<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27765282</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Florez, Helena</dc:author>
<dc:author>Guañabens, Núria</dc:author>
<dc:author>Peris, Pilar</dc:author>
<dc:description xml:lang="en">Fibrous dysplasia is a skeletal disorder that is associated with a wide spectrum of clinical manifestations, including localized asymptomatic forms and extensive severe forms with severe bone deformities and endocrinological alterations, depending on age, location, extent and associated processes. Although the treatment of choice is based on bisphosphonates, the therapeutic efficacy of these agents in the control of disease activity remains uncertain. This article reviews the current data available on the treatment of this disease as well as the preliminary data on new therapeutic approaches.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>McCune-Albright syndrome</dc:subject>
<dc:subject>FGF-23</dc:subject>
<dc:subject>Bisfosfonatos</dc:subject>
<dc:subject>Fibrous dysplasia</dc:subject>
<dc:subject>Displasia fibrosa</dc:subject>
<dc:subject>Denosumab</dc:subject>
<dc:subject>Bisphosphonates</dc:subject>
<dc:subject>Síndrome de McCune-Albright</dc:subject>
<dc:date>2016 Dec 16 </dc:date>
<dc:title xml:lang="es">Displasia fibrosa. Revisión clínica y abordaje terapéutico.</dc:title>
<dc:title xml:lang="en">Fibrous dysplasia. Clinical review and therapeutic management.</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
